From: The use of ICU resources in CAR-T cell recipients: a hospital-wide study
N (%) or Median [IQR] | Overall (n = 71) |
---|---|
Demographics | |
Age | 60 [37–67.5] |
Male gender | 42 (59%) |
Comorbidities | |
Hypertension | 10 (14%) |
Diabetes | 3 (4%) |
Chronic kidney disease | 2 (3%) |
Body mass index (kg/m2) | 24 [22–26] |
ECOG Performance status | |
Median PS | 1 [1–2] |
PS 0 | 11 (15.5%) |
PS 1 | 32 (45%) |
PS 2 | 22 (31%) |
PS 3 | 6 (8.5%) |
Hematological malignancy | |
Diffuse large B cell lymphoma | 53 (75%) |
Lymphoblastic leukemia | 17 (24%) |
Multiple myeloma | 1 (1%) |
Time between hematological diagnosis and ICU admission (months) | 12 [10–16] |
Previous hematological treatments | |
Number of treatment lines prior to CAR-T cells | 3 [3–4] |
Autologous stem cell transplantation | 10 |
Bone marrow transplantation | 5 |
Blinatumomab | 11 |
CAR-T cell therapy | |
Autologous CAR-T cells | 69 |
Axicabtagene ciloleucel | 33 (46%) |
Tisagenlecleucel | 31 (44%) |
Brexucabtagene autoleucel | 4 (5.5%) |
bb2121 | 1 (1.5%) |
Allogeneic CAR-T cells (UCART19) | 2 (3%) |
Time between CAR-T cell infusion and ICU admission (days) | 6 [4–7] |
Clinical and biological features at ICU admission | |
Mean arterial blood pressure (mmHg) | 68 [60–81] |
Temperature (°C) | 39.5 [38.5–40] |
Neutropenia | 47 (66%) |
SOFA score | 4 [2–6] |